|Articles|June 22, 2017
PAREXEL is Acquired by Pamplona Capital Management
Advertisement
PAREXEL International Corporation announced that Pamplona Capital Management, LLP has acquired all of its outstanding shares, including Parexel's net debt, for $88.10 per share in cash-valued at approximately $5 billion.
Read the full release
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
FDA Outlines New Superiority Standard for Future CAR-T Approvals
2
2025 Veeva R&D and Quality Summit: Advancing Site Efficiency and Collaboration in the Next Era of Clinical Trials
3
ACT Brief: Governance-Driven eCOA Acceleration, Site Operations Innovation, and New Momentum for Earlier CAR-T
4
ACT Brief: New CAR-T Trial Requirements, Pfizer Advances Oral GLP-1 Strategy, and Kisqali Shows Durable Long-Term Control
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
